RT Journal Article
SR Electronic
T1 Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.20.20198192
DO 10.1101/2020.09.20.20198192
A1 Manuel Linares
A1 Ramón Pérez-Tanoira
A1 Juan Romanyk
A1 Felipe Pérez-García
A1 Peña Gómez-Herruz
A1 Teresa Arroyo
A1 Juan Cuadros
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.20.20198192.abstract
AB Background Real-time reverse transcription polymerase chain reaction (RT-qPCR) is the current recommended laboratory method to diagnose SARS-CoV-2 acute infection, several factors such as requirement of special equipment, time consuming, high cost and skilled staff limit the use of these molecular techniques. A more rapid and high-throughput method is in growing demand.Methods Evaluate the performances of the Panbio™ COVID-19 AG Rapid Test Device (Nasopharyngeal), a rapid immunochromatographic test for the detection of SARS-CoV-2 antigen, in comparison to RT-qPCR.Results The RDT evaluated in this study showed a high sensitivity and specificity in samples mainly obtained during the first week of symptoms and with high viral loads.Conclusions This assay seems to be an effective strategy for controlling the COVID-19 pandemic for the rapid identification and isolation of SARS-CoV-2 infected patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the ethical requirements established by the Declaration of Helsinki. The Ethics Committee of Hospital Universitario Principe de Asturias (Madrid) approved the study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, M.Linares, upon reasonable request.COVID-19Coronavirus disease 2019SARS-CoV-2Severe acute respiratory syndrome coronavirus 2NPNucleocapsid proteinLFALateral flow assayFDAFood and Drug AdministrationRT-qPCRReal-time reverse transcription polymerase chain reactionRDTRapid diagnostic test.